Semaglutide-treated participants in the phase 3 ESSENCE trial (part 1) have greater concordance of non-invasive test improvements compared with placebo

Mary E. Rinella¹; Manal F. Abdelmalek²; Elisabetta Bugianesi³; Laurent Castera^4,5; Kristiane A. Engebretsen⁶; Jacob George⁷; Wah Kheong Chan⁸; Niels Krarup⁶; Michelle T. Long⁶; Philip N. Newsome^9,10; Cláudia P. Oliveira¹¹; Georgios Papatheodoridis¹²; Ahsan Shoeb⁶; Salvatore Petta¹³; Michael Roden^14,15,16; Arun J. Sanyal¹⁷; Yusuf Yilmaz¹⁸; Vlad Ratziu¹⁹; on behalf of the ESSENCE study group